Drug intelligence / Profile preview

beta-blocker + diuretic + angiotensin-converting enzyme inhibitor + angiotensin receptor blocker

Development stage
Discontinued
Lead developer
Servier
Modality
Small Molecules
Administration
Oral
01

Overview

This is a hypothetical or non-standard combination drug consisting of four antihypertensive agents from different classes: - A beta-blocker, which reduces heart rate and cardiac output by blocking beta-adrenergic receptors. - A diuretic (typically a thiazide), which lowers blood pressure by promoting sodium and water excretion. - An angiotensin-converting enzyme (ACE) inhibitor, which decreases the production of angiotensin II, leading to vasodilation and reduced blood pressure. - An angiotensin receptor blocker (ARB), which blocks the action of angiotensin II at its receptor, also resulting in vasodilation. While combinations of two or three antihypertensive agents are common in clinical practice—such as ACE inhibitor plus diuretic, ARB plus diuretic, or beta-blocker plus diuretic—simultaneous use of both an ACE inhibitor and an ARB is generally not recommended due to increased risk for adverse effects without additional benefit. There are no known approved fixed-dose combination products containing all four classes together[1][2][3][4]. This combination would be used only under exceptional circumstances with careful monitoring.

02

Targets

AGTR1 (Angiotensin II Type-1 receptor)ACE (Angiotensin Converting Enzyme)ADRB1 (β1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on beta-blocker + diuretic + angiotensin-converting enzyme inhibitor + angiotensin receptor blocker.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beta-blocker + diuretic + angiotensin-converting enzyme inhibitor + angiotensin receptor blocker.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call